Citations

Showing 10 of 108083 citations.

Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer
Enomoto, Keisuke , Zhu, Xuguang , Park, Sun‐Mi , Zhao, Li , Qi, Jun , Copland, John A. , Cheng, Sheue-yann, Zhu, Yuelin Jack , Willingham, Mark C. , Meltzer, Paul S. , Cheng, Sheue-yann

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 6, 2017 | Volume: 102 | Issue: 7 | Pages: 2268-2280

10.1210/jc.2016-3771 | PMID 28368473 Get It

Abstract Context: Recent studies showed that transcription of the MYC gene is driven by the interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. JQ1, a potent inhibitor that effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. The role of MYC in human ATC and whether JQ1 can effectively target MYC as a treatment modality have not been elucidated. Objective: To understand the underlying molecular mechanisms of JQ1, we evaluated its efficacy in human ATC cell lines and xenograft models. Design: We determined the effects of JQ1 on proliferation and invasion in cell lines and xenograft tumors. We identified key regulators critical for JQ1-affected proliferation and invasion of tumor cells. Results: JQ1 markedly inhibited proliferation of four ATC cell lines by suppression of MYC and elevation of p21and p27 to decrease phosphorylated Rb and delay cell cycle progression from the G0/G1 phase to the S phase. JQ1 blocked cell invasion by attenuating epithelial-mesenchymal transition signals. These cell-based studies were further confirmed in xenograft studies in which the size and rate of tumor growth were inhibited by JQ1 via inhibition of p21-cyclin/cyclin-dependent kinase-Rb-E2F signaling. Conclusions: These results suggest targeting of the MYC protein could be a potential treatment modality for human ATC for which effective treatment options are limited.
Mixed integer programming with dose‐volume constraints in intensity‐modulated proton therapy
Zhang, Pengfei , Fan, Neng , Shan, Jie , Bues, Martin , Schild, Steven E. , Liu, Wei , Bues, Martin

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 6, 2017 | Volume: 18 | Issue: 5 | Pages: 29-35

10.1002/acm2.12130 | PMID 28681976 Get It

AbstractBackgroundIn treatment planning for intensity‐modulated proton therapy (IMPT), we aim to deliver the prescribed dose to the target yet minimize the dose to adjacent healthy tissue. Mixed‐integer programming (MIP) has been applied in radiation therapy to generate treatment plans. However, MIP has not been used effectively for IMPT treatment planning with dose‐volume constraints. In this study, we incorporated dose‐volume constraints in an MIP model to generate treatment plans for IMPT.MethodsWe created a new MIP model for IMPT with dose volume constraints. Two groups of IMPT treatment plans were generated for each of three patients by using MIP models for a total of six plans: one plan was derived with the Limited‐memory Broyden–Fletcher–Goldfarb–Shanno (L‐BFGS) method while the other plan was derived with our MIP model with dose‐volume constraints. We then compared these two plans by dose‐volume histogram (DVH) indices to evaluate the performance of the new MIP model with dose‐volume constraints. In addition, we developed a model to more efficiently find the best balance between tumor coverage and normal tissue protection.ResultsThe MIP model with dose‐volume constraints generates IMPT treatment plans with comparable target dose coverage, target dose homogeneity, and the maximum dose to organs at risk (OARs) compared to treatment plans from the conventional quadratic programming method without any tedious trial‐and‐error process. Some notable reduction in the mean doses of OARs is observed.ConclusionsThe treatment plans from our MIP model with dose‐volume constraints can meet all dose‐volume constraints for OARs and targets without any tedious trial‐and‐error process. This model has the potential to automatically generate IMPT plans with consistent plan quality among different treatment planners and across institutions and better protection for important parallel OARs in an effective way.
Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience
Gamez, Mauricio E. , Jeans, Elizabeth B. , Hinni, Michael L., Moore, Eric J. , Young, Geoffrey D., McGee, L.A. , Buras, Matthew , Patel, Samir H. , Moore, Eric, Young, Geoffrey, Ma, Daniel, McGee, Lisa, Daniel, J. , Buras, Matthew R

Mayo Clinic

The Laryngoscope | July 6, 2017 | Volume: 128 | Issue: 2 | Pages: 373-377

10.1002/lary.26725 | PMID 28681992 Get It

Objectives/HypothesisSarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes.Study DesignRetrospective study. Median follow‐up 45 months.MethodsThere were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression‐free survival (PFS), and local control (LC) were conducted using the Kaplan‐Meier method.ResultsThe majority of patients were elderly males (92%) with a smoking history (74%) presenting with early‐stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high‐risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3–75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five‐year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II–IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039).ConclusionsSarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early‐stage tumors are treated appropriately with single‐modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.Level of Evidence4. Laryngoscope, 128:373–377, 2018
Selective Cervical Denervation for Cervical Dystonia: Modification of the Bertrand Procedure
Wilson, Thomas J. , Spinner, Robert J.

Mayo Clinic

Operative Neurosurgery | July 6, 2017 | Volume: 14 | Issue: 5 | Pages: 546-555

10.1093/ons/opx147 | PMID 29106650 Get It

Abstract BACKGROUND Cervical dystonia, commonly referred to as spasmodic torticollis, is a neurological disorder characterized by aberrant, involuntary contraction of the muscles of the neck and shoulders. One surgical option that can be considered is selective cervical denervation. OBJECTIVE To report our modification of the Bertrand procedure for selective cervical denervation. METHODS Our modification of the Bertrand procedure for selective cervical denervation is reported with intraoperative photographs and schematic depictions of the operative steps. RESULTS We report our modification of the Bertrand procedure for selective cervical denervation, which consists of a combination of C2-6 denervation, myectomy of the splenius capitis and/or semispinalis capitis, myotomy of the levator scapulae when indicated, and myotomy and selection denervation of the sternocleidomastoid. The combination of techniques utilized depends on the subtype and severity of cervical dystonia. CONCLUSION Our modification of the original Bertrand procedure for selective cervical denervation represents an alternative surgical strategy for the treatment of cervical dystonia, with the potential advantages and disadvantages discussed.
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
Burotto, Mauricio , Edgerly, Maureen, Velarde, Margarita, Drabkin, Harry A., Gormaz, Juan G. , O’Sullivan, Ciara C. , Madan, Ravi A. , Fojo, Tito , O'Sullivan, Ciara, Balasubramaniam, Sanjeeve

Mayo Clinic

The Oncologist | July 6, 2017 | Volume: 22 | Issue: 8 | Pages: 888-e84

10.1634/theoncologist.2017-0211 | PMID 28679644 Get It

Abstract Lessons Learned Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments. The observation of three responses among the 30 patients with median progression-free survival and overall survival of 8.3 and 15 months, respectively, indicates the combination has some activity, but it is not sufficient for further development. Background Treatment of metastatic renal cell carcinoma (mRCC) remains suboptimal. Preclinical data have previously shown that ixabepilone, a microtubule-stabilizing agent approved for the treatment of breast cancer, is active in taxane-sensitive and -resistant cells. In this single-arm phase II trial, we investigated a combination of ixabepilone plus bevacizumab in patients with refractory mRCC. Methods We enrolled 30 patients with histologically confirmed mRCC, clear cell subtype, who had not been previously treated with ixabepilone or bevacizumab but had received at least one prior U.S. Food and Drug Administration (FDA)-approved treatment for renal cell carcinoma (RCC). The treatment regimen consisted of 6 mg/m2 ixabepilone per day for 5 days and 15 mg/kg bevacizumab every 21 days. After 6 cycles, the treatment interval could be extended to every 28 days. The primary endpoint was the objective response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and the toxicity of the combination. Results The median number of prior therapies was two (range per patient one to five). Patients received a median of 8 cycles of ixabepilone plus bevacizumab (range 2–54). The median follow-up was 36.4 months (range 23.5–96.5). Nineteen patients (63.3%) had stable disease as a best response. Three patients (10%) had a partial response. The median PFS was 8.3 months (95% confidence interval [CI], 4.9–10.6) and the median OS was 15.0 months (95% CI, 11.3–28.8). The total number of cycle for safety evaluation was 289. Grade 3/4 adverse events (>5% incidence) included lymphopenia (16.7%), hypertension (6.7%), and leukopenia (6.7%). Conclusion The combination of ixabepilone and bevacizumab was well tolerated, with modest activity in second - or later-line mRCC, but it is not recommended as a therapy without further clinical development. Alternative combinations with these agents could be explored in future studies.
Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
Domingo‐Musibay, Evidio , Heun, James M., Nevala, Wendy K. , Callstrom, Matthew R. , Atwell, Thomas D. , Callstrom, Matthew, Atwell, Thomas, Galanis, Evanthia , Erickson, Lori A. , Markovic, Svetomir N.

Mayo Clinic

The Oncologist | July 6, 2017 | Volume: 22 | Issue: 9 | Pages: 1026-e93

10.1634/theoncologist.2017-0060 | PMID 28679643 Get It

Abstract Lessons Learned Percutaneous thermal ablation combined with in situ granulocyte-macrophage colony-stimulating factor cytokine therapy was technically feasible and well tolerated. No significant clinical or immunologic responses were seen. Background Melanoma tumor-derived heat-shock proteins (HSPs) and HSP-peptide complexes can elicit protective antitumor responses. The granulocyte-macrophage colony-stimulating factor (GM-CSF) chemokine can also promote uptake and processing by professional antigen presenting cells (APCs). On this basis, we designed a pilot study of percutaneous thermal ablation as a means to induce heat-shock protein vaccination plus GM-CSF to determine safety and preliminary antitumor activity of this combination. Materials and Methods This study was designed to assess overall safety of percutaneous ablation combined with GM-CSF for unresectable, metastatic melanoma including uveal and mucosal types. All patients received heat-shock therapy (42°C for 30 minutes), then received one of three treatments: (a) intralesional GM-CSF (500 mcg standard dose); (b) radiofrequency ablation (RFA) + GM-CSF; or (c) cryoablation plus GM-CSF. The primary endpoint of the study was the induction of endogenous HSP70 and melanoma-specific cytotoxic T lymphocytes (CTL). Results Nine patients (three per study arm) were enrolled. No dose-limiting toxicity was observed as specified per protocol. All patients developed progressive disease and went on to receive alternative therapy. Median overall survival (OS) was 8.2 months (95% confidence interval [CI] 2–17.2). The study was not powered to detect a difference in clinical outcome among treatment groups. Conclusion Percutaneous thermal ablation plus GM-CSF was well tolerated, technically feasible, and demonstrated an acceptable adverse event profile comparable to conventional RFA and cryoablation. While HSP70 was induced following therapy, the degree of HSP70 elevation was not associated with clinical outcome or induced CTL responses. While percutaneous thermal ablation plus GM-CSF combinations including checkpoint inhibitors could be considered in future studies, the use of GM-CSF remains experimental and for use in the context of clinical trials.
An analysis of the Arc CHECK ‐ MR diode array's performance for ViewRay quality assurance
Ellefson, S.T., Culberson, Wesley S. , DeWerd, Larry A. , Bayouth, John E. , Ellefson, Steven T, Bednarz, Bryan P.

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 6, 2017 | Volume: 18 | Issue: 4 | Pages: 161-171

10.1002/acm2.12107 | PMID 28681448 Get It

Abstract The Arc CHECK ‐ MR diode array utilizes a correction system with a virtual inclinometer to correct the angular response dependencies of the diodes. However, this correction system cannot be applied to measurements on the ViewRay MR ‐ IGRT system due to the virtual inclinometer's incompatibility with the ViewRay's multiple simultaneous beams. Additionally, the Arc CHECK 's current correction factors were determined without magnetic field effects taken into account. In the course of performing ViewRay IMRT quality assurance with the Arc CHECK , measurements were observed to be consistently higher than the ViewRay TPS predictions. The goals of this study were to quantify the observed discrepancies and test whether applying the current factors improves the Arc CHECK 's accuracy for measurements on the ViewRay. Gamma and frequency analysis were performed on 19 ViewRay patient plans. Ion chamber measurements were performed at a subset of diode locations using a PMMA phantom with the same dimensions as the Arc CHECK . A new method for applying directionally dependent factors utilizing beam information from the ViewRay TPS was developed in order to analyze the current Arc CHECK correction factors. To test the current factors, nine ViewRay plans were altered to be delivered with only a single simultaneous beam and were measured with the Arc CHECK . The current correction factors were applied using both the new and current methods. The new method was also used to apply corrections to the original 19 ViewRay plans. It was found the Arc CHECK systematically reports doses higher than those actually delivered by the ViewRay. Application of the current correction factors by either method did not consistently improve measurement accuracy. As dose deposition and diode response have both been shown to change under the influence of a magnetic field, it can be concluded the current Arc CHECK correction factors are invalid and/or inadequate to correct measurements on the ViewRay system.
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia, X. , Bose, Ron , Gao, Feng , Telli, Melinda L. , Kimmick, Gretchen , Russell, Christy , Cobleigh, Melody , Forero, Andres , Anders, Carey K. , Thomas, Shana , Anderson, J. L. , Bumb, Caroline, Banks, Kimberly C. , Bryce, Richard , Lalani, Alshad S. , Pfeifer, John D. , Hayes, Daniel F. , Pegram, Mark D. , Blackwell, Kimberly , Bédard, Philippe L. , Al‐Kateb, Hussam , Freedman, Rachel A. , Winer, Eric P. , Naughton, Michael J. , Goetz, Matthew P. , Tripathy, Debu , Pluard, Timothy , Niravath, Polly Ann , Anderson, Jill, Lanman, Richard B. , Ellis, Matthew J. , Banks, Kimberly C , Gao, Feng , Telli, Melinda L

Mayo Clinic

Clinical Cancer Research | July 5, 2017 | Volume: 23 | Issue: 19 | Pages: 5687-5695

10.1158/1078-0432.ccr-17-0900 | PMID 28679771 Get It

Abstract Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) HER2mut detection. Experimental Design: Tumor tissue positive for HER2mut was required for eligibility. Neratinib was administered 240 mg daily with prophylactic loperamide. ctDNA sequencing was performed retrospectively for 54 patients (14 positive and 40 negative for tumor HER2mut). Results: Nine of 381 tumors (2.4%) sequenced centrally harbored HER2mut (lobular 7.8% vs. ductal 1.6%; P = 0.026). Thirteen additional HER2mut cases were identified locally. Twenty-one of these 22 HER2mut cases were estrogen receptor positive. Sixteen patients [median age 58 (31–74) years and three (2–10) prior metastatic regimens] received neratinib. The CBR was 31% [90% confidence interval (CI), 13%–55%], including one CR, one PR, and three SD ≥24 weeks. Median PFS was 16 (90% CI, 8–31) weeks. Diarrhea (grade 2, 44%; grade 3, 25%) was the most common adverse event. Baseline ctDNA sequencing identified the same HER2mut in 11 of 14 tumor-positive cases (sensitivity, 79%; 90% CI, 53%–94%) and correctly assigned 32 of 32 informative negative cases (specificity, 100%; 90% CI, 91%–100%). In addition, ctDNA HER2mut variant allele frequency decreased in nine of 11 paired samples at week 4, followed by an increase upon progression. Conclusions: Neratinib is active in HER2mut, nonamplified MBC. ctDNA sequencing offers a noninvasive strategy to identify patients with HER2mut cancers for clinical trial participation. Clin Cancer Res; 23(19); 5687–95. ©2017 AACR.
Illness Understanding of Oncology Patients in a Community-Based Cancer Institute
Sivendran, Shanthi , Jenkins, Sarah M. , Svetec, Sarah, Horst, Michael, Newport, Kristina , Yost, Kathleen J. , Yang, Manshu

Mayo Clinic

Journal of Oncology Practice | July 5, 2017 | Volume: 13 | Issue: 9 | Pages: e800-e808

10.1200/jop.2017.020982 | PMID 28678589 Get It

Purpose: Several studies have demonstrated that patients have a poor understanding of prognosis, survival, and effectiveness of chemotherapy, particularly in the setting of advanced cancer. This study examines oncology patients’ understanding of their illness based on accurate reporting of stage at diagnosis and knowledge of cancer status (ie, free of cancer or in remission v active disease). Materials and Methods: Two hundred eight patients with cancer previously treated at our large community-based cancer institute participated in the Consumer-Based Cancer Care Value Index field survey. Electronic medical record documentation of stage at diagnosis and cancer status was compared with patients’ self-reported responses. Concordance of responses and variables influencing discordance were evaluated. Results: In 51.0% of patients, self-reported cancer stage matched the abstracted stage, with the highest concordance in patients with advanced cancer (72%) versus patients with stage I to III disease (36.4% to 61.5%). Unexpectedly, discordance was lower among patients with advanced cancer compared with patients with stage I to III cancer ( P = .0528). Patients who were concordant for cancer stage at diagnosis were significantly more likely to be female ( P = .001), be younger than age 65 years ( P = .01), have an income > $60,000 ( P = .03), and have more education ( P = .02). In 64.4% of patients, self-reported cancer status (ie, free of cancer or in remission v active disease) matched the abstracted status. Nearly 30% of patients were not sure about their status, even when they were free of cancer or in remission. Conclusion: Our findings confirm that more than one quarter of patients with advanced cancer have poor illness understanding and highlight that an even greater number of patients with early stage I to III cancer have poor illness understanding. These observations highlight the need to improve illness understanding for patients across the entire cancer continuum.
The metabolic syndrome alters the miRNA signature of porcine adipose tissue‐derived mesenchymal stem cells
Eirin, Alfonso , Zhu, Xiangyang , Chanana, Pritha , Wijnen, André J. van , Lerman, Lilach O. , Meng, Yu , Tang, Hui Ru , Lerman, Amir , van Wijnen, Andre J , Eirin, Alfonso

Mayo Clinic

Cytometry Part A | July 5, 2017 | Volume: 93 | Issue: 1 | Pages: 93-103

10.1002/cyto.a.23165 | PMID 28678424 Get It

AbstractAutologous transplantation of mesenchymal stem cells (MSCs) is a viable option for the treatment of several diseases. Evidence indicates that MSCs release extracellular vesicles (EVs) and that EVs shuttle miRNAs to damaged parenchymal cells to activate an endogenous repair program. We hypothesize that comorbidities may interfere with the packaging of cargo in MSC‐derived EVs. Therefore, we examined whether metabolic syndrome (MetS) modulates the miRNA content packed within MSC‐derived EVs. MSCs were collected from swine abdominal adipose tissue after 16 weeks of lean or obese diet (n = 7 each). Next‐generation RNA sequencing of miRNAs (miRNA‐seq) was performed to identify miRNAs enriched in MSC‐derived EVs and their predicted target genes. Functional pathway analysis of the top 50 target genes of the top 4 miRNAs enriched in each group was performed using gene ontology analysis. Lean‐ and MetS‐EVs were enriched in, respectively, 14 and 8 distinct miRNAs. Target genes of miRNAs enriched in MetS‐EVs were implicated in the development of MetS and its complications, including diabetes‐related pathways, validated transcriptional targets of AP1 family members Fra1 and Fra2, Class A/1 (Rhodopsin‐like receptors), and Peptide ligand‐binding receptors. In contrast, miRNAs enriched in Lean EVs target primarily EphrinA‐EPHA and the Rho family of GTPases. MetS alters the miRNA content of EVs derived from porcine adipose tissue MSCs. These alterations could impair the efficacy and limit the therapeutic use of autologous MSCs in subjects with MetS. Our findings may assist in developing adequate regenerative strategies to preserve the reparative potency of MSCs in individuals with MetS. © 2017 International Society for Advancement of Cytometry